Drug:
Reaction: ACCIDENTAL EXPOSURE TO PRODUCT
20250101 - 20251231
No. 1101 - 1200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1101 | 25000472 |
US |
49 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1102 | 25000474 |
US |
8 | 2 |
Pyrexia, Vomiting, Nausea, Headache, Eczema, Hypersensitivity, Inappropriate schedule of product administration, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1103 | 25000491 |
US |
38 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DOCUSATE SODIUM, SENNOSIDES, DOCUSATE SODIUM AND SENNOSIDES, SENNOSIDES AND DOCUSATE SODIUM, DOCUSATE SODIUM SENNOSIDES, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, MEDROXYPROGESTERONE ACETATE, INSULIN GLARGINE-YFGN, INSULIN GLARGINE, SPIRONOLACTONE, INSULIN LISPRO, SEMAGLUTIDE, |
||||
| 1104 | 25000510 |
US |
1 | |
Accidental exposure to product, Rash, |
||||
EVOLOCUMAB, |
||||
| 1105 | 25000560 |
US |
2 | |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 1106 | 25000598 |
US |
15 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1107 | 25000680 |
US |
24 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1108 | 25000693 |
US |
47 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1109 | 25000724 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1110 | 25000776 |
US |
60 | 2 |
Injection site pain, Injection site swelling, Injection site haemorrhage, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1111 | 25000800 |
US |
10 | 1 |
Injection site haemorrhage, Nasopharyngitis, Pyrexia, Rhinorrhoea, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1112 | 25000811 |
US |
51 | 2 |
Exposure via skin contact, Accidental exposure to product, Incorrect route of product administration, |
||||
DUPILUMAB, |
||||
| 1113 | 25000860 |
US |
19 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1114 | 25000925 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 1115 | 25000983 |
US |
18 | 1 |
Injection site erythema, Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1116 | 25001081 |
US |
47 | 2 |
Skin exfoliation, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1117 | 24992585 |
DE |
||
Device leakage, Product dose omission issue, Accidental exposure to product, |
||||
GUSELKUMAB, |
||||
| 1118 | 24992741 |
US |
53 | 1 |
Accidental exposure to product, |
||||
MEPOLIZUMAB, |
||||
| 1119 | 24992781 |
US |
2 | |
No adverse event, Product packaging issue, Accidental exposure to product, Product dose omission issue, Product physical issue, |
||||
IXAZOMIB, IXAZOMIB, |
||||
| 1120 | 24992863 |
US |
51 | 2 |
Device deployment issue, Accidental exposure to product, Underdose, |
||||
GUSELKUMAB, |
||||
| 1121 | 24993089 |
US |
53 | 1 |
Accidental exposure to product, |
||||
OFATUMUMAB, |
||||
| 1122 | 24993327 |
US |
2 | |
Accidental exposure to product, Device leakage, Incorrect dose administered by device, |
||||
OFATUMUMAB, |
||||
| 1123 | 24993433 |
US |
59 | 1 |
Accidental exposure to product, Device mechanical issue, Device malfunction, |
||||
ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, |
||||
| 1124 | 24993826 |
US |
2 | |
Device issue, Accidental exposure to product, Product dose omission issue, |
||||
SECUKINUMAB, |
||||
| 1125 | 24993973 |
US |
69 | 2 |
Pruritus, Skin discolouration, Skin burning sensation, Accidental exposure to product, |
||||
LEVALBUTEROL, LEVALBUTEROL HYDROCHLORIDE, BUDESONIDE, |
||||
| 1126 | 24994625 |
US |
51 | 2 |
Chemical burns of eye, Chemical burn of skin, Eye pain, Ocular hyperaemia, Product confusion, Accidental exposure to product, Device connection issue, |
||||
IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, ERGOCALCIFEROL, ALPRAZOLAM, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, LORAZEPAM, MAGNESIUM, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, SILDENAFIL CITRATE, SILDENAFIL, LITHIUM CARBONATE, VITAMIN A, COPPER, CUPRIC CHLORIDE, QUETIAPINE, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, BOSENTAN, GABAPENTIN, SOLIFENACIN SUCCINATE, ESCITALOPRAM, LORATADINE, LORATADINE ORAL, |
||||
| 1127 | 24995350 |
US |
62 | 1 |
Wrong technique in product usage process, Accidental exposure to product, Cough, Syringe issue, |
||||
OMALIZUMAB, OMALIZUMAB, GLIPIZIDE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, LOSARTAN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 1128 | 24995401 |
US |
64 | 2 |
Burning sensation, Pruritus, Dry skin, Accidental exposure to product, Exposure via skin contact, |
||||
LIFITEGRAST, CYCLOSPORINE, |
||||
| 1129 | 24995402 |
US |
2 | |
Accidental exposure to product, Device leakage, Exposure via skin contact, Drug delivery system malfunction, |
||||
SECUKINUMAB, |
||||
| 1130 | 24995465 |
US |
78 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 1131 | 24995736 |
US |
82 | 2 |
Accidental exposure to product, Injury associated with device, Wrong technique in product usage process, Device difficult to use, Drug dose omission by device, Pain, |
||||
ETANERCEPT, |
||||
| 1132 | 24996938 |
US |
2 | |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Underdose, |
||||
BELIMUMAB, |
||||
| 1133 | 24997091 |
US |
2 | |
Device malfunction, Device leakage, Accidental exposure to product, |
||||
SECUKINUMAB, |
||||
| 1134 | 24988299 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, Incorrect dose administered by device, Device leakage, Device malfunction, |
||||
ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, |
||||
| 1135 | 24988406 |
US |
2 | |
Injection site haemorrhage, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered by device, Device leakage, |
||||
ADALIMUMAB-ADAZ, |
||||
| 1136 | 24988519 |
US |
2 | |
Accidental exposure to product, |
||||
IBUPROFEN, |
||||
| 1137 | 24988655 |
US |
||
Eye irritation, Accidental exposure to product, Product quality issue, Product dose omission issue, Off label use, |
||||
MINOXIDIL, OIL, |
||||
| 1138 | 24988813 |
US |
34 | 1 |
Injection site pain, Wrong technique in device usage process, Incorrect dose administered, Accidental exposure to product, |
||||
BELIMUMAB, |
||||
| 1139 | 24988826 |
US |
78 | 2 |
Device difficult to use, Accidental exposure to product, Incorrect dose administered by device, Injection site bruising, Injection site haemorrhage, Injection site swelling, Abdominal discomfort, |
||||
EVOLOCUMAB, CLOPIDOGREL, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 1140 | 24989001 |
US |
73 | 1 |
Accidental exposure to product, Needle issue, Device defective, Drug dose omission by device, Device leakage, |
||||
OFATUMUMAB, DALFAMPRIDINE, LEVOTHYROXINE, ROPINIROLE, SERTRALINE, |
||||
| 1141 | 24989238 |
US |
88 | 1 |
Incorrect dose administered, Product administered at inappropriate site, Inappropriate schedule of product administration, Product container issue, Accidental exposure to product, Poor quality product administered, |
||||
| 1142 | 24989286 |
US |
38 | 2 |
Product dose omission issue, Accidental exposure to product, Product complaint, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 1143 | 24989362 |
US |
2 | |
Device malfunction, No adverse event, Wrong technique in product usage process, Accidental exposure to product, |
||||
OMALIZUMAB, |
||||
| 1144 | 24989543 |
US |
45 | 2 |
Exposure via skin contact, Accidental exposure to product, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 1145 | 24989840 |
US |
2 | |
Accidental exposure to product, Device defective, Device malfunction, |
||||
SECUKINUMAB, |
||||
| 1146 | 24989905 |
US |
2 | |
Accidental exposure to product, |
||||
LEUPROLIDE ACETATE, |
||||
| 1147 | 24990140 |
US |
2 | |
Accidental exposure to product, |
||||
SECUKINUMAB, |
||||
| 1148 | 24990358 |
US |
32 | 2 |
Device difficult to use, Wrong technique in product usage process, Accidental exposure to product, Drug dose omission by device, Intentional product misuse, Contusion, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, ONABOTULINUMTOXINA, ATOGEPANT, |
||||
| 1149 | 24990652 |
US |
2 | |
Needle issue, Device issue, Injury associated with device, Accidental exposure to product, Incorrect dose administered by device, Off label use, |
||||
CANAKINUMAB, CANAKINUMAB, CANAKINUMAB, CANAKINUMAB, |
||||
| 1150 | 24990861 |
US |
1 | |
Accidental exposure to product, Needle issue, Product dose omission issue, Device defective, |
||||
SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, |
||||
| 1151 | 24991736 |
US |
2 | |
Device defective, Accidental exposure to product, Drug dose omission by device, |
||||
SECUKINUMAB, SECUKINUMAB, |
||||
| 1152 | 24992107 |
US |
1 | |
Device malfunction, Device dispensing error, Accidental exposure to product, |
||||
SECUKINUMAB, |
||||
| 1153 | 24992226 |
US |
75 | 1 |
Injection site indentation, Wrong technique in product usage process, Accidental exposure to product, Drug dose omission by device, Incorrect disposal of product, Product communication issue, |
||||
EVOLOCUMAB, SEMAGLUTIDE, TESTOSTERONE, TESTOSTERONE,, |
||||
| 1154 | 24992295 |
US |
2 | |
Accidental exposure to product, |
||||
SECUKINUMAB, |
||||
| 1155 | 24992313 |
US |
||
Accidental exposure to product, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 1156 | 24983277 |
US |
14 | 1 |
Injection site discharge, Incorrect dose administered, Accidental exposure to product, Device issue, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 1157 | 24983597 |
US |
77 | 2 |
Device difficult to use, Wrong technique in product usage process, Product communication issue, Contusion, Accidental exposure to product, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 1158 | 24984059 |
US |
42 | 1 |
Underdose, Accidental exposure to product, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 1159 | 24984248 |
US |
||
Accidental exposure to product, Device issue, |
||||
ONABOTULINUMTOXINA, |
||||
| 1160 | 24984639 |
US |
||
Chest discomfort, Dyspnoea, Accidental exposure to product, Product packaging difficult to open, Product substitution issue, Pruritus, |
||||
SPIRONOLACTONE, FUROSEMIDE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, TIOTROPIUM BROMIDE, |
||||
| 1161 | 24984884 |
US |
56 | 1 |
Colour blindness, Accidental exposure to product, Device difficult to use, Product administration error, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 1162 | 24984907 |
US |
42 | 1 |
Device issue, Incorrect dose administered, No adverse event, Accidental exposure to product, Needle issue, Syringe issue, Product administration error, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 1163 | 24984923 |
US |
1 | |
Device delivery system issue, Exposure via skin contact, Wrong technique in device usage process, Device leakage, Accidental exposure to product, Incorrect dose administered, Product complaint, Drug delivery system malfunction, |
||||
MEPOLIZUMAB, |
||||
| 1164 | 24984962 |
US |
1 | |
Accidental exposure to product, Wrong technique in product usage process, |
||||
DICLOFENAC SODIUM, |
||||
| 1165 | 24985056 |
US |
50 | 2 |
Accidental exposure to product, Injection site pain, Pain, Pruritus, Paraesthesia, Off label use, Needle issue, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, |
||||
| 1166 | 24985167 |
US |
7 | 2 |
Renal failure, Hypotension, Toxicity to various agents, Accidental exposure to product, Electrocardiogram QT prolonged, |
||||
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE TABLES AF, SOTALOL HYDROCHLORIDE TABLETS AF, WARFARIN, WARFARIN, |
||||
| 1167 | 24985225 |
US |
1 | |
Accidental exposure to product, Device difficult to use, Drug dose omission by device, Injection site indentation, |
||||
EVOLOCUMAB, |
||||
| 1168 | 24985449 |
US |
66 | 2 |
Device deployment issue, Accidental exposure to product, Product dose omission issue, |
||||
GOLIMUMAB, |
||||
| 1169 | 24985457 |
US |
17 | 2 |
Accidental exposure to product, Syringe issue, Device defective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, MONTELUKAST, FAMOTIDINE, |
||||
| 1170 | 24985475 |
US |
1 | |
Needle issue, Accidental exposure to product, Product dose omission issue, |
||||
SECUKINUMAB, IBUPROFEN SODIUM, IBUPROFEN, IBUPROFEN TABLETS, COATED, IBUPROFEN TABLET COATED, |
||||
| 1171 | 24985648 |
US |
35 | 2 |
Device deployment issue, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 1172 | 24986073 |
US |
77 | 1 |
Myocardial infarction, Stent placement, Laryngectomy, Gastrointestinal tube insertion, Device difficult to use, Drug dose omission by device, Device use error, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 1173 | 24986186 |
US |
37 | 2 |
Product dose omission issue, Hyperventilation, Accidental exposure to product, Device malfunction, Needle issue, |
||||
OMALIZUMAB, |
||||
| 1174 | 24986210 |
US |
13 | 2 |
Exposure via skin contact, Accidental exposure to product, Incorrect dose administered by device, Drug dose omission by device, Device leakage, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 1175 | 24986440 |
US |
2 | |
Device malfunction, Accidental exposure to product, Incorrect dose administered by device, Device leakage, |
||||
SECUKINUMAB, |
||||
| 1176 | 24986842 |
US |
51 | 2 |
Injection site pain, Accidental exposure to product, Wrong technique in product usage process, Device difficult to use, Incorrect dose administered by device, Product administered at inappropriate site, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 1177 | 24987334 |
US |
86 | 2 |
Neoplasm progression, Muscle spasms, Pain, Product prescribing error, Poor quality product administered, Product physical issue, Accidental exposure to product, Exposure via skin contact, |
||||
ENCORAFENIB, ENCORAFENIB, ENCORAFENIB, |
||||
| 1178 | 24987349 |
US |
1 | |
Needle issue, Drug dose omission by device, Accidental exposure to product, Device leakage, |
||||
SECUKINUMAB, |
||||
| 1179 | 24987653 |
US |
2 | |
Product packaging issue, Device leakage, Accidental exposure to product, |
||||
SECUKINUMAB, |
||||
| 1180 | 24987707 |
US |
1 | |
Accidental exposure to product, |
||||
GALCANEZUMAB-GNLM, |
||||
| 1181 | 24987725 |
US |
2 | |
Inappropriate schedule of product administration, Accidental exposure to product, Device issue, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 1182 | 24987764 |
US |
40 | |
Product dose omission issue, Accidental exposure to product, Injection site haemorrhage, Needle issue, Accidental exposure to product, Injection site haemorrhage, |
||||
GUSELKUMAB, |
||||
| 1183 | 24978505 |
CA |
53 | 2 |
Device deployment issue, Accidental exposure to product, Product dose omission issue, |
||||
GOLIMUMAB, |
||||
| 1184 | 24978525 |
US |
42 | 2 |
Accidental exposure to product, Wrong technique in product usage process, Injection site discharge, |
||||
ADALIMUMAB, |
||||
| 1185 | 24978555 |
US |
17 | |
Accidental exposure to product, Product use issue, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 1186 | 24978607 |
US |
72 | 2 |
Injection site pain, Injection site discolouration, Injection site erythema, Accidental exposure to product, Device use error, Incorrect dose administered by device, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 1187 | 24978704 |
US |
77 | 2 |
Injection site haemorrhage, Injury associated with device, Accidental exposure to product, Device difficult to use, Wrong technique in product usage process, Drug dose omission by device, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 1188 | 24978729 |
US |
||
Exposure via skin contact, Accidental exposure to product, |
||||
BELIMUMAB, |
||||
| 1189 | 24978782 |
US |
67 | 1 |
Incorrect dose administered by device, Accidental exposure to product, Injection site haemorrhage, Device difficult to use, |
||||
ETANERCEPT, |
||||
| 1190 | 24979140 |
US |
90 | 2 |
Incorrect disposal of product, Eye pain, Drug dose omission by device, Accidental exposure to product, Device difficult to use, |
||||
EVOLOCUMAB, |
||||
| 1191 | 24979805 |
US |
2 | |
Accidental exposure to product, Device malfunction, Drug dose omission by device, |
||||
SECUKINUMAB, METOPROLOL TARTRATE, |
||||
| 1192 | 24979883 |
US |
58 | 2 |
Exposure via skin contact, Skin burning sensation, Headache, Weight decreased, Respiratory tract congestion, Fatigue, Accidental exposure to product, Product leakage, Product leakage, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, MACITENTAN, ARNICA MONTANA FLOWER, SILDENAFIL CITRATE, SILDENAFIL, SILDENAFIL POWDER,, ERGOCALCIFEROL, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, CHLORPHENIRAMINE MALEATE, DIAZEPAM, DIAZEPAM ORAL, DIAZEPAM ORAL SOLUTION (CONCENTRATE), SPIRONOLACTONE, OXYGEN, 0XYGEN, LORATADINE, LORATADINE ORAL, VITAMIN C, |
||||
| 1193 | 24980123 |
US |
2 | |
Accidental exposure to product, |
||||
IBUPROFEN, IBUPROFEN AND DIPHENHYDRAMINE CITRATE, |
||||
| 1194 | 24980420 |
US |
34 | 1 |
Needle issue, Accidental exposure to product, Drug dose omission by device, |
||||
SECUKINUMAB, |
||||
| 1195 | 24980702 |
US |
43 | 2 |
Incorrect dose administered by device, Accidental exposure to product, Device difficult to use, Injection site pain, |
||||
ERENUMAB-AOOE, |
||||
| 1196 | 24981708 |
US |
72 | 1 |
Eye disorder, Accidental exposure to product, Device difficult to use, Drug dose omission by device, Device use error, Incorrect disposal of product, |
||||
EVOLOCUMAB, |
||||
| 1197 | 24981734 |
US |
59 | 1 |
Needle issue, Device delivery system issue, Accidental exposure to product, |
||||
ABATACEPT, |
||||
| 1198 | 24982216 |
US |
21 | 1 |
Needle issue, Product leakage, Pain, Drug dose omission by device, Accidental exposure to product, |
||||
SECUKINUMAB, |
||||
| 1199 | 24982444 |
US |
2 | |
Device malfunction, Drug dose omission by device, Needle issue, Accidental exposure to product, |
||||
SECUKINUMAB, |
||||
| 1200 | 24982770 |
US |
2 | |
Accidental exposure to product, Drug dose omission by device, Device issue, |
||||
SECUKINUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28